Compare ARKO & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | EVMN |
|---|---|---|
| Founded | 1970 | 2020 |
| Country | United States | United States |
| Employees | 9748 | 48 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 737.0M | 717.5M |
| IPO Year | N/A | N/A |
| Metric | ARKO | EVMN |
|---|---|---|
| Price | $7.73 | $23.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $7.50 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 874.3K | 442.1K |
| Earning Date | 05-07-2026 | 06-11-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $56.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $13.89 |
| 52 Week High | $8.76 | $33.20 |
| Indicator | ARKO | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 58.92 |
| Support Level | $7.32 | $21.32 |
| Resistance Level | $7.95 | $25.50 |
| Average True Range (ATR) | 0.38 | 1.52 |
| MACD | -0.09 | 0.51 |
| Stochastic Oscillator | 23.10 | 71.04 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.